Biogen (NASDAQ: BIIB) reported third-quarter 2020 financial results before the opening bell on Wednesday. The biotechnology giant reported a 6% decline in Q3 revenues to $3.38 billion, beating the Wall Street consensus. Earnings of $8.84 per share were also stronger than what analysts had anticipated.
BIIB shares were trading flat immediately following the announcement. The stock has slipped 9% since the beginning of this year.
Biogen also lowered its guidance for the full year, hurt by multiple Tecfidera generic entrants in the US.
Prior performance
Most Popular
KinderCare Learning Companies to offer 24 Mln shares for $23-27 in US IPO
In 2024, the IPO market shifted to recovery mode, with a significant increase in activity compared to last year when it witnessed a slowdown. Encouraged by the booming stock market
Constellation Brands’ (STZ) beer business remains resilient in a tough environment
Shares of Constellation Brands, Inc. (NYSE: STZ) gained 1% on Friday. The stock has dropped 4% over the past three months. The beverages giant delivered better-than-expected earnings results for the
What to look for when Charles Schwab (SCHW) reports Q3 2024 results
Financial services company The Charles Schwab Corporation (NYSE: SCHW) is preparing to report third-quarter results on October 14, with experts predicting a mixed outcome. As part of its long-term succession
